Alzamend Neuro Stock Price

-0.71 (-12.39%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.71 -12.39% 5.02 13:35:53
Open Price Low Price High Price Close Price Prev Close
5.28 4.87 5.29 5.73
Bid Price Ask Price Spread News
5.03 5.07 0.04 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,862 1,876,124 $ 5.05 $ 9,465,647 - 4.85 - 33.55
Last Trade Time Type Quantity Stock Price Currency
13:37:03 3 $ 5.05 USD


Draw Mode:

Alzamend Neuro Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 428.23M 85.30M 27.91M $ - $ - -0.05 -104.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Alzamend Neuro News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALZN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.978.284.855.697,404,172-0.95-15.91%
1 Month9.0512.144.857.094,253,868-4.03-44.53%
3 Months29.0033.554.857.523,266,605-23.98-82.69%
6 Months29.0033.554.857.523,266,605-23.98-82.69%
1 Year29.0033.554.857.523,266,605-23.98-82.69%
3 Years29.0033.554.857.523,266,605-23.98-82.69%
5 Years29.0033.554.857.523,266,605-23.98-82.69%

Alzamend Neuro Description

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient's immunological system to combat Alzheimer's.

Your Recent History
Alzamend N..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.